Pfizers keys to juggling 8 U.S. launches? Organization, accountability, clear goals

Think you are busy. Take a look at Pfizers commercial team for oncology, which is currently launching four new drugs, three new indications for older drugs, and a biosimilar. And that’s just in the U.S. Its taken some serious internal organizing on Pfizer’s part, but so far managing the multiple rollouts has been done very well, according to Andy Schmeltz, global president and general manager of Pfizer’s oncology unit. “Certainly you can only have one top priority at a time, and I think we’ve tried to be thoughtful in making sure that we organize ourselves internally so that there can be key priorities,” Schmeltz said in a recent interview. “Division of labor, accountability and clear goals” are all vital pieces of the equation, he added.

Spotlight

Spotlight

Related News